NEW YORK (GenomeWeb) – Biocept announced today that it has signed agreements to sell $9.3 million in stock and warrants to certain institutional investors.

According to the company, it will sell about 4.3 million shares of its common stock at $2.15 per share, as well as warrants to purchase up to roughly 2.2 million shares of common stock at an exercise price of $2.50 a share. The warrants are exercisable six months after the close of the transaction and expire five years from the date they become exercisable.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.